Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

2 of 0 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Early Phase 1
1(25.0%)
4Total
Phase 1(3)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05478837Phase 1Active Not Recruiting

Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma

Role: collaborator

NCT07007117Phase 1Recruiting

PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma

Role: collaborator

NCT03585764Phase 1Terminated

MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Role: collaborator

NCT00361296Early Phase 1Terminated

Vaccine Therapy in Treating Patients With Myelodysplastic Syndromes

Role: collaborator

All 4 trials loaded